Jonathan Aschoff
Stock Analyst at Roth Capital
(0.50)
# 4,190
Out of 5,146 analysts
38
Total ratings
25%
Success rate
-35.55%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Buy | $57 | $23.40 | +143.59% | 1 | Nov 25, 2025 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.46 | +2,307.53% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $8.90 | +135.96% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $199,800 → $106,560 | $7.39 | +1,441,848.58% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $0.24 | +7,375.08% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $1.69 | +42,148.52% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $500 | $1.64 | +30,387.80% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $2.57 | +38,810.51% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $3.45 | +24,247.83% | 4 | Mar 28, 2024 | |
| HSDT Solana Company | Maintains: Buy | $3,750 → $18,000 | $1.95 | +922,976.92% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $12.20 | +145.90% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $4.98 | +3,913.97% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $8.84 | +58.37% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28,800 → $86,400 | $1.35 | +6,399,900.00% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.86 | +330.11% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.82 | +5,394.51% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.89 | +44,874.14% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $6.40 | +494.21% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.81 | +5,218.56% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.36 | +859.41% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Nov 25, 2025
Initiates: Buy
Price Target: $57
Current: $23.40
Upside: +143.59%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.46
Upside: +2,307.53%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $8.90
Upside: +135.96%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $199,800 → $106,560
Current: $7.39
Upside: +1,441,848.58%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $0.24
Upside: +7,375.08%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $1.69
Upside: +42,148.52%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $500
Current: $1.64
Upside: +30,387.80%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $2.57
Upside: +38,810.51%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $3.45
Upside: +24,247.83%
Solana Company
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $1.95
Upside: +922,976.92%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $12.20
Upside: +145.90%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $4.98
Upside: +3,913.97%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $8.84
Upside: +58.37%
Feb 14, 2023
Maintains: Buy
Price Target: $28,800 → $86,400
Current: $1.35
Upside: +6,399,900.00%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.86
Upside: +330.11%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $1.82
Upside: +5,394.51%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.89
Upside: +44,874.14%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $6.40
Upside: +494.21%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.81
Upside: +5,218.56%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.36
Upside: +859.41%